Search research articles
Contact Us
Filters
Showing results (1-10 of 220) with videos related to
Page
of 22
Sort By:
Circulation
|
October 28, 2024
Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials
Elisabetta Patorno
Endocrine Reviews
|
March 12, 2021
Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
Sebastian Schneeweiss, Elisabetta Patorno
BMJ (Clinical Research Ed.)
|
October 20, 2021
Time to end the misuse of race in medicine: cases from nephrology
Chandrasekar Gopalakrishnan, Elisabetta Patorno
Annals of Internal Medicine
|
December 20, 2021
Web Exclusive. Annals On Call - SGLT2 Versus GLP1 for Cardiovascular Prevention
Robert M Centor, Elisabetta Patorno
BMJ (Clinical Research Ed.)
|
August 1, 2014
Authors' reply to Gupta
Elisabetta Patorno, Brian T Bateman
JAMA Internal Medicine
|
May 28, 2024
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Nephrolithiasis in Clinical Practice-Reply
Julie M Paik, Elisabetta Patorno
The New England Journal of Medicine
|
June 8, 2017
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno
American Journal of Epidemiology
|
May 21, 2022
Pradhan et al. Respond to "Large-Scale, Multisite Studies Using Real-World Data"
Richeek Pradhan, Elisabetta Patorno, Laurent Azoulay
Clinical and Translational Gastroenterology
|
November 19, 2021
Misclassification of Obesity in Claims Data
Karine Suissa, Seoyoung C Kim, Elisabetta Patorno
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 13, 2021
Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes
Tracey G Simon, Elisabetta Patorno, Sebastian Schneeweiss
Page
of 22
Search research articles
Search
Showing results (1-10 of 220) with videos related to
Sort By:
Page
of 22
Circulation
|
October 28, 2024
Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials
Elisabetta Patorno
Endocrine Reviews
|
March 12, 2021
Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
Sebastian Schneeweiss, Elisabetta Patorno
BMJ (Clinical Research Ed.)
|
October 20, 2021
Time to end the misuse of race in medicine: cases from nephrology
Chandrasekar Gopalakrishnan, Elisabetta Patorno
Annals of Internal Medicine
|
December 20, 2021
Web Exclusive. Annals On Call - SGLT2 Versus GLP1 for Cardiovascular Prevention
Robert M Centor, Elisabetta Patorno
BMJ (Clinical Research Ed.)
|
August 1, 2014
Authors' reply to Gupta
Elisabetta Patorno, Brian T Bateman
JAMA Internal Medicine
|
May 28, 2024
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Nephrolithiasis in Clinical Practice-Reply
Julie M Paik, Elisabetta Patorno
The New England Journal of Medicine
|
June 8, 2017
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno
American Journal of Epidemiology
|
May 21, 2022
Pradhan et al. Respond to "Large-Scale, Multisite Studies Using Real-World Data"
Richeek Pradhan, Elisabetta Patorno, Laurent Azoulay
Clinical and Translational Gastroenterology
|
November 19, 2021
Misclassification of Obesity in Claims Data
Karine Suissa, Seoyoung C Kim, Elisabetta Patorno
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 13, 2021
Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes
Tracey G Simon, Elisabetta Patorno, Sebastian Schneeweiss
Page
of 22